Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 1.00 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.93 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.61 |
| ▸ | PPARG | P37231 | 7/20 | 0.61 |
| ▸ | PPARD | Q03181 | 7/20 | 0.61 |
| ▸ | PPARA | Q07869 | 7/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TLR2 | O60603 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | FABP4 | P15090 | 2/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770529 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G2AGPR84PPARGPPARD | |
| SCHEMBL28776220 | 0.96 | PLA2G2A (1.00) | PLA2G4APLA2G2AGPR84PPARGPPARD | |
| SCHEMBL4795104 | 0.91 | PLA2G4A (0.82) | PLA2G4APLA2G2APPARGPPARDPPARA | |
| SCHEMBL4927236 | 0.91 | PLA2G4A (0.82) | PLA2G4APLA2G2APPARGPPARDPPARA | |
| SCHEMBL12636328 | 0.89 | PLA2G2A (0.79) | PLA2G4APLA2G2AEPHX2 | |
| SCHEMBL29449856 | 0.84 | PLA2G4A (0.73) | PLA2G4APLA2G2AKMT2AEPHX2 | |
| SCHEMBL7155979 | 0.81 | EPHX2 (0.76) | PLA2G4AGPR84PPARGPPARDPPARA | |
| SCHEMBL12836993 | 0.81 | EPHX2 (0.76) | PLA2G4AGPR84PPARGPPARDPPARA | |
| SCHEMBL2769524 | 0.81 | EPHX2 (0.76) | PLA2G4AGPR84PPARGPPARDPPARA | |
| SCHEMBL15297165 | 0.81 | EPHX2 (0.76) | PLA2G4AGPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614144-B1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTION | TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2015-07-22 | — | — | EP | claimed |
| US-7745489-B2 | Compositions and methods for inhibition of phospholipase A2 mediated inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-29 | — | — | US | claimed |
| EP-1490328-A4 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | UNIV CALIFORNIA (US) | 2007-08-15 | — | — | EP | claimed |
| US-20050148549-A1 | Compositions and methods for inhibition of phospholipase a2 mediated inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-07 | — | — | US | claimed |
| EP-1490328-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | The Regents of The University of California (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003076389-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-09-18 | — | — | WO | claimed |
| EP-2614144-B1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTION | TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8420852-B2 | Phospholipase A2 inhibitors and their use in treating neurological injury and disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110105610-A1 | Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-05-05 | — | — | US | disclosed |
| US-7745489-B2 | Compositions and methods for inhibition of phospholipase A2 mediated inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2009009449-A2 | PHOSPHOLIPASE A2 INHIBITORS AND THEIR USE IN TREATING NEUROLOGICAL INJURY AND DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
| EP-1937247-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1490328-A4 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | UNIV CALIFORNIA (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007022443-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20050148549-A1 | Compositions and methods for inhibition of phospholipase a2 mediated inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-07 | — | — | US | disclosed |
| EP-1490328-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | The Regents of The University of California (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003076389-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | PLA2G4A 1/4885PLA2G2A 3/4885GPR84 593/4885 |
| US-20050148549-A1 | Compositions and methods for inhibition of phospholipase a2 mediated inflammation | PLA2G4A, PLA2G4B, PLA2G1B | PLA2G4A 1/4885PLA2G2A 5/4885GPR84 1047/4885 |
| US-20110105610-A1 | Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and Disease | PLA2G4A, PLA2G4B, PLA2G2A | PLA2G4A 1/4885PLA2G2A 3/4885GPR84 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.